| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Sofiniclin targets the α4β2 nicotinic acetylcholine receptor (nAChR), the most abundant nAChR subtype in the brain. α4β2 nAChRs are pentameric ligand-gated ion channels composed of α4 and β2 subunits that mediate fast synaptic transmission and modulate neurotransmitter release. These receptors are involved in cognitive processes including attention, learning, and memory. Sofiniclin is a selective agonist of the α4β2 nAChR with an IC50 of 0.1 nM. The compound binds with high affinity to the α4β2 receptor and activates receptor-mediated ion flux. Sofiniclin has Ki values of 1.9 nM for the α-conotoxin MII binding site and 1.3 nM for epibatidine binding. The compound's selectivity for α4β2 over other nAChR subtypes supports its utility for studying α4β2-mediated cognitive functions.
|
|---|---|
| ln Vitro |
With Ki values of 1.3 nM for 125I-epibatidine binding and 1.9 nM for 125I-α-conotoxinMII binding, sofiniclin is more potent than ABT-089 at both receptor subtypes[1].
Sofiniclin demonstrates potent in vitro activity as an α4β2 nAChR agonist. The compound has an IC50 of 0.1 nM for the α4β2 nAChR. Sofiniclin binds with Ki values of 1.9 nM for the α-conotoxin MII binding site and 1.3 nM for epibatidine binding, confirming high affinity for the receptor. Sofiniclin is more potent than ABT-089 on both receptor subtypes. The compound's potent and selective α4β2 nAChR agonism makes it a valuable tool for studying the role of α4β2 nAChRs in cognitive function and neuropsychiatric disorders. Sofiniclin shows promise in enhancing cognitive functions such as attention, memory, and working memory. |
| ln Vivo |
Compared to a vehicle monkey, sofiniclin (0.001 to 0.10 mg/kg, po) significantly lowers LIDs[1]. Monkeys with extensive nigrostriatal injury do not have a reduction in LIDs when given sofiniclin (0.1 mg/kg)[2].
Sofiniclin has been evaluated in vivo for its effects on cognitive function and attention. The compound is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD). Sofiniclin showed promising effects on attention, working memory, and executive function in early clinical trials, including studies for Alzheimer's disease, ADHD, and age-related cognitive decline. At 0.1 mg/kg, Sofiniclin does not decrease LIDs in monkeys with severe nigrostriatal damage. The compound's oral activity and cognitive-enhancing effects support its utility for in vivo studies. Detailed in vivo efficacy data are available in the primary literature. |
| Enzyme Assay |
The in vitro receptor binding assay for Sofiniclin measures the compound's binding affinity to α4β2 nAChRs. Membrane preparations from cells expressing human α4β2 nAChRs or rat brain tissue are incubated with varying concentrations of Sofiniclin in the presence of radiolabeled ligands such as [125I]α-conotoxin MII or [125I]epibatidine. The amount of bound radioligand is measured by scintillation counting, and Ki values are determined by fitting competition binding curves (1.9 nM for α-conotoxin MII binding site, 1.3 nM for epibatidine binding). The compound is dissolved in DMSO and diluted in assay buffer. Selectivity is assessed by testing the compound against other nAChR subtypes. Appropriate positive controls and negative controls are included in each assay run.
|
| Cell Assay |
The in vitro functional assay for Sofiniclin measures the compound's agonist activity at α4β2 nAChRs. Cells expressing human α4β2 nAChRs or Xenopus oocytes injected with α4 and β2 subunit cRNAs are treated with varying concentrations of Sofiniclin or vehicle control. Receptor activation is measured by assessing ion flux (e.g., calcium influx using fluorescent calcium indicators or electrophysiological recordings). The EC50 or IC50 for receptor activation is determined (0.1 nM). The compound's effects on downstream signaling pathways can also be assessed. Dose-response relationships are established by analyzing receptor activation across different compound concentrations.
|
| Animal Protocol |
In vivo animal experiments with Sofiniclin are conducted using rodent or non-human primate models of cognitive impairment, ADHD, or age-related cognitive decline. Sofiniclin is administered orally or intraperitoneally at various doses. Cognitive function is assessed using behavioral tasks such as the five-choice serial reaction time task (attention), novel object recognition (memory), and other cognitive tests. The compound's effects on attention, working memory, and executive function are evaluated. The compound's effects on LIDs (levodopa-induced dyskinesias) can also be assessed at doses such as 0.1 mg/kg. Detailed experimental protocols are described in the primary literature.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic (PK) parameters for Sofiniclin are not extensively documented in publicly available sources. The compound is orally active. Sofiniclin has a molecular weight of 256.11 (free base) and a chemical formula of C10H11Cl2N3. The compound is soluble in DMSO for formulation purposes. For in vivo oral administration, Sofiniclin is typically formulated using appropriate vehicles to ensure adequate solubility and stability. The compound should be stored under conditions recommended by the manufacturer to maintain stability and prevent degradation. Detailed PK parameters including half-life, clearance, volume of distribution, and maximum concentration (Cmax) are available in the primary literature and should be consulted for specific experimental planning.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for Sofiniclin are not extensively documented in publicly available sources. As a research-grade compound, Sofiniclin is intended for laboratory research purposes only and is not approved for human therapeutic use. Standard laboratory safety practices should be followed when handling this compound, including the use of appropriate personal protective equipment and working in a well-ventilated area. The compound should be stored according to the manufacturer's recommendations to maintain stability and prevent degradation. Comprehensive toxicological profiling (e.g., LD50, maximum tolerated dose, organ-specific toxicity) is not available from the current search results and would require consultation of the primary literature or safety data sheets.
|
| References | |
| Additional Infomation |
Sofinicline has been used in trials to study the treatment of attention deficit hyperactivity disorder, neuralgia, diabetes, diabetic neuropathy, diabetic polyneuropathy, and diabetic neuropathic pain.
Sofiniclin is a research compound developed for studying the role of α4β2 nAChRs in cognitive function and for evaluating α4β2 agonists as potential treatments for ADHD and other cognitive disorders. The compound is also known as ABT-894. Sofiniclin is a selective agonist of the α4β2 nAChR with an IC50 of 0.1 nM. The compound showed promising effects on attention, working memory, and executive function in early clinical trials. Sofiniclin is not currently in clinical trials nor approved for therapeutic use; it remains an investigational tool compound for preclinical neuroscience research. Sofiniclin is available from various chemical suppliers for research purposes. |
| Molecular Formula |
C10H11N3CL2
|
|---|---|
| Molecular Weight |
244.12044
|
| Exact Mass |
243.033
|
| Elemental Analysis |
C, 49.20; H, 4.54; Cl, 29.04; N, 17.21
|
| CAS # |
799279-80-4
|
| Related CAS # |
799279-87-1;799279-85-9 (tartrate);869792-84-7 (acetate);869792-87-0 (mesylate); 869792-90-5 (HCl); 799279-80-4; 876170-44-4 (besylate);
|
| PubChem CID |
10131048
|
| Appearance |
Off-white to brown solid powder
|
| LogP |
2.19
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
251
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
ClC1C(Cl)=NC=C(N2C[C@H]3NC[C@H]3C2)C=1
|
| InChi Key |
MBQYQLWSBRANKQ-IMTBSYHQSA-N
|
| InChi Code |
InChI=1S/C10H11Cl2N3/c11-8-1-7(3-14-10(8)12)15-4-6-2-13-9(6)5-15/h1,3,6,9,13H,2,4-5H2/t6-,9+/m0/s1
|
| Chemical Name |
(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane
|
| Synonyms |
Sofinicline; ABT-894; A-422894.0; ABT 894; A-422894; ABT894; A 422894.0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~35.71 mg/mL (~146.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0963 mL | 20.4817 mL | 40.9635 mL | |
| 5 mM | 0.8193 mL | 4.0963 mL | 8.1927 mL | |
| 10 mM | 0.4096 mL | 2.0482 mL | 4.0963 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA